New Issue: Orbital Catastrophe Ahead? Read Now

Schizophrenia Drugs Questioned

Join Our Community of Science Lovers!

Donald F. Klein of Columbia University remembers handing out the first pills for schizophrenia in 1955, when the only treatment was electroshock therapy. One patient, an institutionalized war veteran who had not spoken in decades, swallowed the medication and a few days later suddenly asked, “When am I getting out of this place?”

According to a new study, this early class of drugs may work just as well at reducing hallucinations and delusions as modern pills that cost up to 10 times more. In the early 1990s the new medications, such as Zyprexa and Seroquel, took over, promising greater effectiveness and less debilitating side effects, including tremors. The federal government sponsored the $43-million study as a check against the results of previous tests that had been sponsored by drug companies and as a way to evaluate Medicaid’s payout for high-priced schizophrenia medication, one of the program’s biggest expenses.

Overseen by Columbia’s director of psychiatry, Jeffrey A. Lieberman, the study randomly assigned one of five drugs—four from the new class, one from the old—to 1,460 chronically ill patients and followed them for 18 months. Lieberman’s team found that all five compounds were about equally effective. And at moderate doses, at least, adverse reactions from the old medication, Trilafon, were no worse than for the others.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Perhaps the biggest surprise, however, was that none of the pharmaceuticals satisfied patients. Almost 75 percent of the participants quit treatment, were taken out by their doctors or asked to be switched to another pill, because symptoms were not improving or side effects were intolerable. “We clearly need better drugs,” Lieberman says.

Although the old medications can cause tremors, stiffness and jerky muscle movements, the new medicines bring problems, too: weight gain and increased blood glucose, cholesterol and triglyceride levels, which put patients at risk for diabetes or heart disease. The rates of these side effects vary, so until better pills are actually devised, treatment may continue to be less than optimum.

SA Mind Vol 16 Issue 4This article was published with the title “Schizophrenia Drugs Questioned” in SA Mind Vol. 16 No. 4 (), p. 8
doi:10.1038/scientificamericanmind1205-8a

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe